# Phase 2 Carcinoma, Renal Cell trials recruiting: 84 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 84 trials in phase 2 for Carcinoma, Renal Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Carcinoma, Renal Cell trials: 84 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/carcinoma-renal-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 84
- Recruiting or not yet: 84
- Read on: November 19, 2026

## Trials

The 25 newest of 84, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07937553 | Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma. | Kidney Cancer Research Bureau | Phase 2 | Recruiting | Metastatic Chromophobe Renal Cell Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937553) |
| November 10, 2026 | NCT07928167 | Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients | Kidney Cancer Research Bureau | Phase 2 | Recruiting | Metastatic Renal Cell Carcinoma ( mRCC) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928167) |
| November 9, 2026 | NCT07925333 | Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer | Beth Israel Deaconess Medical Center | Phase 2 | Not yet recruiting | Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925333) |
| November 6, 2026 | NCT07922915 | Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Localized Clear Cell Renal Cell Carcinoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922915) |
| November 2, 2026 | NCT07909265 | Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell Carcinoma | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909265) |
| October 16, 2026 | NCT07877194 | A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer | Summit Therapeutics | Phase 2 | Not yet recruiting | Renal Cell Carcinoma, Clear Cell | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877194) |
| October 13, 2026 | NCT07870746 | Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 2 | Not yet recruiting | ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870746) |
| September 24, 2026 | NCT07840001 | Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma | Peter MacCallum Cancer Centre, Australia | Phase 2 | Not yet recruiting | Locally Advanced Clear Cell Renal Cell Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840001) |
| September 18, 2026 | NCT07828704 | Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA | Henry Ford Health System | Phase 2 | Recruiting | Kidney Cancers | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828704) |
| September 14, 2026 | NCT07816770 | MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas | Fudan University | Phase 2 | Not yet recruiting | Metastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary Carcinomas | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816770) |
| August 20, 2026 | NCT07776717 | TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal... | Fudan University | Phase 2 | Not yet recruiting | Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776717) |
| July 20, 2026 | NCT07715565 | Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell... | West China Hospital | Phase 2 | Not yet recruiting | Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715565) |
| June 4, 2026 | NCT07627464 | Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Renal Cell Carcinoma (RCC) | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627464) |
| May 22, 2026 | NCT07602101 | Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma | RenJi Hospital | Phase 2 | Not yet recruiting | Clear Cell Renal Cell Carcinoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602101) |
| May 18, 2026 | NCT07593040 | Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma | Vall d'Hebron Institute of Oncology | Phase 2 | Not yet recruiting | Renal Cell Carcinoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07593040) |
| May 11, 2026 | NCT07578025 | Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | City of Hope Medical Center | Phase 2 | Not yet recruiting | Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07578025) |
| May 8, 2026 | NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576725) |
| May 6, 2026 | NCT07571551 | Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma | Jinling Hospital, China | Phase 2 | Recruiting | Clear Cell RCC | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07571551) |
| April 8, 2026 | NCT07516366 | Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516366) |
| April 3, 2026 | NCT07510334 | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Mayo Clinic | Phase 2 | Recruiting | Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510334) |
| March 27, 2026 | NCT07494435 | Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | Zhejiang Haichang Biotech Co., Ltd. | Phase 2 | Not yet recruiting | Hepato Cellular Carcinoma (HCC), Renal Cell Cancer | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07494435) |
| March 13, 2026 | NCT07470840 | SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma | Fujian Cancer Hospital | Phase 2 | Not yet recruiting | Locally Advanced or Metastatic Renal Cell Carcinoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07470840) |
| March 13, 2026 | NCT07469683 | An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib... | Yonsei University | Phase 2 | Recruiting | Clear Cell Renal Cell Carcinoma, Neoplasms, Malignant Neoplasms, Malignant Neoplasm of Kidney, Except Renal Pelvis | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07469683) |
| March 10, 2026 | NCT07460206 | Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment | Gruppo Oncologico Italiano di Ricerca Clinica | Phase 2 | Not yet recruiting | ccRCC | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07460206) |
| February 9, 2026 | NCT07397611 | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | Dana-Farber Cancer Institute | Phase 2 | Recruiting | Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07397611) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 5 |
| M.D. Anderson Cancer Center | 4 |
| City of Hope Medical Center | 4 |
| National Cancer Institute (NCI) | 4 |
| Sun Yat-sen University | 4 |
| Mayo Clinic | 3 |
| Jinling Hospital, China | 3 |
| RenJi Hospital | 3 |
| University of Texas Southwestern Medical Center | 3 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| Kidney Cancer Research Bureau | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| Maria Sklodowska-Curie National Research Institute of Oncology | 1 |
| Peter MacCallum Cancer Centre, Australia | 1 |
| Vall d'Hebron Institute of Oncology | 1 |
| Massachusetts General Hospital | 1 |
| Fujian Cancer Hospital | 1 |
| Yale University | 1 |
| Imbioray (Hangzhou) Biomedicine Co., Ltd. | 1 |
| Tianjin Medical University Second Hospital | 1 |
| [Telix Pharmaceuticals (Innovations) Pty Limited](https://specstream.ai/data/clinical-trials/company/telix-pharmaceuticals-innovations-pty-limited) | 1 |
| Henry Ford Health System | 1 |
| Gruppo Oncologico Italiano di Ricerca Clinica | 1 |
| Vanderbilt-Ingram Cancer Center | 1 |
| West China Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 43 |
| China | 20 |
| Australia | 2 |
| Spain | 2 |
| Italy | 2 |
| Russia | 2 |
| Canada | 2 |
| France | 2 |
| Brazil | 1 |
| South Korea | 1 |
| Puerto Rico | 1 |
| Uganda | 1 |
| Ireland | 1 |
| United Kingdom | 1 |
| Netherlands | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Blueprint printers in the United States](https://specstream.ai/data/businesses/blueprint-printers/united-states)
- [Builders in the United States](https://specstream.ai/data/businesses/builders/united-states)
- [Business schools in the United States](https://specstream.ai/data/businesses/business-schools/united-states)
- [Carpenters in the United States](https://specstream.ai/data/businesses/carpenters/united-states)
- [Child care centers in the United States](https://specstream.ai/data/businesses/child-care-centers/united-states)
- [Closet remodeling companies in the United States](https://specstream.ai/data/businesses/closet-remodeling-companies/united-states)
